Whereas, mDia2 suppression drove alternative modes of tumor cell motility in cervical, ovarian, breast, and prostate cancers, and hepatocarcinoma models (Eisenmann et al., 2007a; Di Vizio et al., 2009; Hager et al., 2012; Wyse et al., 2012; Pettee et al., 2014), glioblastoma cells in vitro and ex vivo spheroid-rat brain slice models showed IMM-induced mDia2 agonism more effectively blocked glioblastoma migration and invasion than antagonism, with no toxicity in rat brain slice explants (Arden et al., 2015). The gene discussed is DIAPH3; the disease is Familial prostate cancer.